CR20140124A - Metabolitos de transclomifeno y usos de los mismos - Google Patents

Metabolitos de transclomifeno y usos de los mismos

Info

Publication number
CR20140124A
CR20140124A CR20140124A CR20140124A CR20140124A CR 20140124 A CR20140124 A CR 20140124A CR 20140124 A CR20140124 A CR 20140124A CR 20140124 A CR20140124 A CR 20140124A CR 20140124 A CR20140124 A CR 20140124A
Authority
CR
Costa Rica
Prior art keywords
metabolites
transclomifen
same
relates
present
Prior art date
Application number
CR20140124A
Other languages
English (en)
Spanish (es)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46724628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CR20140124A publication Critical patent/CR20140124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CR20140124A 2011-08-04 2014-03-13 Metabolitos de transclomifeno y usos de los mismos CR20140124A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515278P 2011-08-04 2011-08-04

Publications (1)

Publication Number Publication Date
CR20140124A true CR20140124A (es) 2014-05-13

Family

ID=46724628

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140124A CR20140124A (es) 2011-08-04 2014-03-13 Metabolitos de transclomifeno y usos de los mismos

Country Status (21)

Country Link
US (1) US9981906B2 (enExample)
EP (2) EP2744777A1 (enExample)
JP (2) JP6433785B2 (enExample)
KR (1) KR20140054110A (enExample)
CN (1) CN103702975B (enExample)
AU (2) AU2012289964B2 (enExample)
BR (1) BR112014000908A2 (enExample)
CA (1) CA2841572C (enExample)
CL (1) CL2014000268A1 (enExample)
CO (1) CO6862154A2 (enExample)
CR (1) CR20140124A (enExample)
EA (1) EA201490416A1 (enExample)
IL (1) IL230287B (enExample)
MX (1) MX355316B (enExample)
MY (2) MY191802A (enExample)
NI (1) NI201400008A (enExample)
PH (1) PH12014500144A1 (enExample)
SG (1) SG10201606425WA (enExample)
UA (1) UA113291C2 (enExample)
WO (1) WO2013020017A1 (enExample)
ZA (1) ZA201400406B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120284764A1 (en) * 2011-05-05 2012-11-08 Keith Ball Method and system for requesting services by a media device
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
EP2854763B1 (en) 2012-05-31 2018-09-26 Repros Therapeutics Inc. Formulations for vaginal delivery of antiprogestins
JP6343619B2 (ja) 2012-11-02 2018-06-13 レプロス セラピューティクス インコーポレイティド プロゲステロン依存性病態を処置する方法およびその組成物
WO2014070523A1 (en) * 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
WO2017123577A1 (en) * 2016-01-12 2017-07-20 Repros Therapeutics Inc. Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions
KR20180112048A (ko) * 2016-02-25 2018-10-11 아스펜 파크 파마슈티컬스 인코포레이티드 클로미펜 이성질체들의 경구 제형 및 이차 생식선 기능저하증 치료를 위하여 이들을 사용하는 방법
WO2017182097A1 (en) 2016-04-22 2017-10-26 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
FI951193L (fi) 1992-09-15 1995-03-14 Merrell Pharma Inc Ei-metabolisoituvat klomifeenianalogit tamoksifeeniresistenttien kasvainten hoitamiseksi
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH10501814A (ja) 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 生物的作用物質用のイン・シツゲル形成デリバリービヒクルおよびその使用方法
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
AU6824996A (en) 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6190591B1 (en) 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
KR20010006026A (ko) 1997-04-03 2001-01-15 존스 홉킨스 유니버시티 스쿨 오브 메디슨 생물분해성 테레프탈레이트 폴리에스테르-폴리(포스페이트) 중합체, 조성물, 약품 및 그의 제조방법과 이용방법
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
EP1100330A4 (en) 1998-07-30 2004-04-14 Stoller Ets TREATMENT OF PLANTS WITH SALICYLIC ACID AND ORGANIC AMINES
ATE355279T1 (de) 1998-08-07 2006-03-15 Novartis Vaccines & Diagnostic Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR20020011437A (ko) 1999-06-11 2002-02-08 추후보정 여성에 비-경구 안드로겐형 스테로이드의 투여
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
AU3104301A (en) 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
RU2342145C2 (ru) 2000-01-28 2008-12-27 Андорешерш, Инк. Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
ES2228932T3 (es) 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
DE60228583D1 (de) 2001-07-09 2008-10-09 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20040235808A1 (en) 2001-09-21 2004-11-25 Jiabing Wang Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20080242726A1 (en) 2004-07-14 2008-10-02 Podolski Joseph S Trans-Clomiphene for the Treatment of Benign Prostate Hypertrophy, Porstate Cancer, Hypogonadism Elevated Triglycerides and High Cholesterol
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
CN101115709B (zh) * 2004-12-13 2011-04-13 小野药品工业株式会社 氨基羧酸衍生物及其医药用途
BRPI0606528A8 (pt) 2005-02-04 2018-03-13 Repros Therapeutics Inc composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
AU2006213856B2 (en) 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
PL383444A1 (pl) * 2005-03-22 2008-03-17 Repros Therapeutics Inc. Sposoby dawkowania trans-klomifenu
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
JP2009503096A (ja) * 2005-08-05 2009-01-29 リプロス セラピューティクス インコーポレイテッド クロミフェンを用いる女性不妊症を処置するための方法および組成物
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
US20080112888A1 (en) 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
WO2009000306A1 (en) 2007-06-26 2008-12-31 Soporte Multivendor S.L. Method and device for managing multicast groups
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
SG185311A1 (en) 2007-10-16 2012-11-29 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US20140235601A1 (en) 2011-08-09 2014-08-21 Kenneth W. Adams Use of Aromatase Inhibitor Or Estrogen Blocker For Increasing Spermatogenesis Or Testosterone Levels In Males
US20150031656A1 (en) 2012-02-29 2015-01-29 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
UA113324C2 (xx) 2012-08-21 2017-01-10 Склади транс-кломіфену та їх застосування
CN103351304B (zh) 2013-07-01 2015-12-09 暨明医药科技（苏州）有限公司 一种克罗米芬的合成方法

Also Published As

Publication number Publication date
US20140163114A1 (en) 2014-06-12
US9981906B2 (en) 2018-05-29
SG10201606425WA (en) 2016-09-29
EP3351527A1 (en) 2018-07-25
CN103702975B (zh) 2016-03-16
CL2014000268A1 (es) 2014-11-14
UA113291C2 (xx) 2017-01-10
NI201400008A (es) 2015-12-10
MX355316B (es) 2018-04-16
BR112014000908A2 (pt) 2017-02-21
HK1196349A1 (zh) 2014-12-12
EP2744777A1 (en) 2014-06-25
NZ621892A (en) 2016-03-31
JP2014529584A (ja) 2014-11-13
ZA201400406B (en) 2014-11-26
PH12014500144A1 (en) 2014-02-24
AU2017204171A1 (en) 2017-07-13
AU2012289964B2 (en) 2017-03-23
AU2012289964A1 (en) 2014-01-30
WO2013020017A1 (en) 2013-02-07
MY191802A (en) 2022-07-15
JP2019023210A (ja) 2019-02-14
IL230287B (en) 2019-07-31
KR20140054110A (ko) 2014-05-08
CO6862154A2 (es) 2014-02-10
EA201490416A1 (ru) 2014-11-28
JP6433785B2 (ja) 2018-12-05
CA2841572C (en) 2020-10-13
MY170718A (en) 2019-08-27
CA2841572A1 (en) 2013-02-07
MX2014000825A (es) 2014-02-27
IL230287A0 (en) 2014-03-06
CN103702975A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
TWD159089S (zh) 錶
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
TWD165137S (zh) 錶
BR112013028512A2 (pt) cápsula
TWD159086S (zh) 錶
UY4175Q (es) Reloj pulsera
TWD159090S (zh) 錶
TWD162033S (zh) 手錶
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
CR20140132A (es) Derivados de pirrolopirimidina y purina
BR112015008272A2 (pt) cápsula para preparação de bebidas
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
TWD159085S (zh) 錶
UY34538A (es) Heteroarilos y usos de los mismos
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
TWD158665S (zh) 錶
DK2880084T3 (da) Fremgangsmåde til klæbning med tynde klæbestoflag
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MX347855B (es) Derivados de anilina, su preparación y su aplicación terapéutica.
BR112014026634A2 (pt) direcionador
CO6862154A2 (es) Metabolitos de trans-clomifeno y usos de los mismos
CO6751286A2 (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
CO6761304A2 (es) Nuevos compuestos de bezodioxol-piperazina